Livzon Pharmaceutical amends governance, reports Q3 2025 results

Livzon Pharmaceutical Group announced the abolition of its supervisory board, with its functions transferred to the board of directors' audit committee. This change, effective October 24, 2025, aligns with the new Company Law and aims to streamline corporate governance, enhancing operational efficiency and compliance. The company will proceed with the industrial and commercial registration changes and file the amended articles of association.

Concurrently, Livzon Pharmaceutical Group has published its third quarter 2025 report. For the nine months ending September 30, 2025, the company reported total revenue of CNY 9,115,914,290.40, a net profit attributable to shareholders of CNY 1,754,100,316.30, and basic earnings per share of CNY 1.96. The company also disclosed share repurchase activities, having bought back 15,376,845 A-shares at a total cost of CNY 570,228,471.25.